Clearview Cancer Institute - Clinical Trials

Quick Links:

Events & Groups:

Clinical Trials

Did you know Clearview Cancer Institute has been involved in Clinical Research for over 18 years? Findings from clinical trial research have led to significant advances in cancer prevention and treatment, and Clearview offers numerous clinical trials whereby patients who volunteer for them receive innovative, state-of-the-art cancer care.

Non-Hodgkins Lymphoma

Genentech U4391g- Phase III Multicenter Study of Rituximab Faster Rate Infusion Time in Patients with Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkins Lymphoma.

Rationale:

Primary objective of this study is to determine the incidence of Grade 3 or 4 infusion-related toxicities resulting from faster infusion of Rituximab in patients who have previously received Rituximab at the standard infusion rate, without experiencing Grade 3 or 4 infusion-related adverse events.

Eligibility:

Must be age 19 or older
Never been treated for DLBC or Follicular Lymphoma
ECOC 0-2
Cannot have significant cardiovascular disease
Must not have grade 2 or higher peripheral neuropathy
To continue on to Cycle 2, must not have grade 3 or higher infusion reaction during cycle 1

Treatment:

Cycle 1, Day 1 is Standard Infusion: R CHOP Rituximab 375mg/m2 on Cycle1, Day 1; if no grade 3 or greater side effects occur then proceed to: Cycles 2-6 or 2-8 R CHOP Rituximab 375mg/m2 20% of dose the first 30 minutes, then remainder 80% over the next 60 minutes.

Contact:

Kathy Cutter, RN, BSN 256-705-4248

Current Clinical Trials:

If you are interested in more information on clinical trials at Clearview, please feel free to contact us (256) 705-4224. More information regarding clinical trials can be found at: www.ClinicalTrials.gov